June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|February 10, 2022
Glaucoma 360: Annual event celebrates research, industry, philanthropy
Author(s)Sheryl Stevenson
Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times®' Sheryl Stevenson on what attendees can expect from this year's annual meeting.
Advertisement
Listen as Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, highlight this year's meeting, from the Annual Gala to the New Horizons Forum to the Glaucoma Symposia.
Advertisement
Related to this article
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
2
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
3
PRIMA at 3 years: Early surgical risk, durable vision gains in GA
4
AAO 2026: What the evidence really shows about nutrition and the eye
5